HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GAO Report Casts Shade On Sunscreen Ingredients' Chances With FDA

This article was originally published in The Rose Sheet

Executive Summary

GAO report requested by leadership of House and Senate committees with oversight of FDA adds evidence behind an argument that the agency's monograph process for sunscreen and other OTC ingredients should be changed substantially to facilitate making more pharmaceutical remedies available nonprescription.

You may also be interested in...



Apotex' Aleve PM Rival Could Have 180-Day Exclusivity As A CGT

US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), the FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.

Latest Aleve PM Copy Could Have 180-Day Exclusivity From More Competition

US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.

Economic Adulteration Underscored In GAO Memory Supplements Study

Audit finds two of three memory supplements tested contain none or lower levels of active supplement than stated on labeling. In a report for current and previous  ranking minority members of Senate Special Committee on Aging, GAO points to continuing issues with economic adulteration for gingko biloba.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel